eResearchTechnology Net Income Up 62%

Tuesday, August 5, 2008 11:19 AM

eResearchTechnology (eRT), a provider of centralized ECG and eClinical technology, ePRO and other services to the pharmaceutical, biotechnology, medical device industries, reported second quarter net income jumped 62.5% to 13 cents a share on revenue that increased 43.4% to a record $35.5 million.

Operating income was up 72.2 % to $10.8 million, compared with the second quarter of 2007. Operating income included a loss of $300,000 from the operations of CCSS and the integration of CCSS into eRT.

New bookings rose 42% to $49 million compared with $34.5 million for the second quarter of 2007. Those new bookings included a record 15 new Thorough ECG study agreements, valued at an average of slightly greater than $900,000 each.

Backlog was also a record at $157.9 million, an increase of $6.5 million from March 31, 2008.

In late morning trading, eResearchTechnology’s shares were up 1.5% to $14.34.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs